Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

@article{Copelan2013BetterLA,
  title={Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.},
  author={Edward A. Copelan and Betty Hamilton and Belinda R. Avalos and Kwang Woo Ahn and Brian James Bolwell and Xiaochun Zhu and Mahmoud Deeb Aljurf and Koen M. van Besien and Christopher N. Bredeson and J. -Y. Cahn and Luciano J Costa and Marcos de Lima and Robert Peter Gale and Gregory A. Hale and Joerg P Halter and Mehdi Hamadani and Yoshihiro Inamoto and Rammurti T. Kamble and Mark R Litzow and Alison W. Loren and David Ian Marks and Eduardo Olavarr{\'i}a and Vivek Roy and Mitchell Sabloff and Bipin N Savani and Matthew D. Seftel and Harry C. Schouten and Celalettin Ustun and Edmund K Waller and Daniel J. Weisdorf and Baldeep Mona Wirk and Mary M. Horowitz and Mukta Arora and Jeff Szer and J. C. Gal{\'a}n Cort{\'e}s and Matt E. Kalaycio and Richard T Maziarz and Wael Saber},
  journal={Blood},
  year={2013},
  volume={122 24},
  pages={3863-70}
}
Cyclophosphamide combined with total body irradiation (Cy/TBI) or busulfan (BuCy) are the most widely used myeloablative conditioning regimens for allotransplants. Recent data regarding their comparative effectiveness are lacking. We analyzed data from the Center for International Blood and Marrow Transplant Research for 1230 subjects receiving a first hematopoietic cell transplant from a human leukocyte antigen-matched sibling or from an unrelated donor during the years 2000 to 2006 for acute… CONTINUE READING